Wikidata

(Q45204128)

English

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

scientific article published in December 2004

In more languages

Statements

title
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
author name string
Rudolf Weide
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
Annette Pandorf
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
Jochen Heymanns
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
Hubert Köppler
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
publication date
1 December 2004
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017
page(s)
2445-2449
1 reference
stated in
Europe PubMed Central
PubMed ID
15621757
retrieved
10 December 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q45204128&oldid=2069807884"